Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotics as Adjuvant in Acute Severe Ulcerative Colitis
NCT03794765Phase 2Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ceftriaxone and metronidazole in ulcerative colitis (UC) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Clinical response as defined by the Oxford's criteria at 48 hours. Started Apr 2019; status: completed.
02
Drugs
ceftriaxonemetronidazole
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03794765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794765.